Wilmer Cutler Pickering Hale and Dorr has advised Biogen. Biogen Inc. (Nasdaq: BIIB) announced that it has entered into a definitive agreement to acquire RayThera Inc.,...
Biogen to Acquire RayThera for Up to $1 Billion
Strategic Partnership Formed Between Nuveen Private Capital, Hunter Point Capital, and Temasek
Debevoise & Plimpton has advised Nuveen, and Macfarlanes has advised Arcmont Asset Management. Nuveen Private Capital, along with Hunter Point Capital and Temasek, has entered into...
Corient Acquires Stakes in Stonehage Fleming and Stanhope Capital to Form Leading Global Wealth Manager
Travers Smith LLP has advised Caledonia Investments plc. Macfarlanes and Borel & Barbey have advised Stonehage Fleming and Stanhope Capital. Walder Wyss and Skadden have advised...
Verona Pharma’s $650 Million Financing Round
Sidley Austin represented OMERS Life Sciences in the transaction, while Latham & Watkins advised Verona Pharma and Sullivan & Cromwell represented Oaktree Capital Management, L.P. Verona...
Janux Therapeutics’ $296.5 Million Common Stock Offering
Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
Keywords Studios’ £76.5 Million Acquisition of The Multiplayer Group From Improbable Worlds Ltd
Macfarlanes advised Improbable Worlds Limited while DWF acted for Keywords Studios on the deal. Keywords Studios, the international provider of creative and technology-enabled solutions to the...
PMG’s Acquisition of RocketMill
Macfarlanes advised PMG on its acquisition of RocketMill. PMG has acquired UK-based RocketMill, a leading independent, full-service digital marketing agency. The combined strengths of PMG and...
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
CytomX’s Research Collaboration With Moderna
Latham & Watkins LLP advised CytomX in the transaction. CytomX Therapeutics, Inc. (NASDAQ: CTMX), a leader in the field of conditionally activated oncology therapeutics and Moderna,...
Distributed Solar Development’s Groundbreaking US$155 Million Securitization
Sidley represented Distributed Solar Development, LLC on the deal. Distributed Solar Development, LLC (“DSD”), a leader in large-scale, custom solar PV and energy storage solutions, announced a...
CytomX’s Collaboration and Licensing Agreement With Regeneron Pharmaceuticals
Latham & Watkins LLP represented CytomX in the transaction. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and CytomX Therapeutics, Inc. (NASDAQ: CTMX) have announced a collaboration and licensing...
Vaxcyte’s $690 Million Public Offering
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...